SAN DIEGO, Nov. 02, 2016 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) will hold its quarterly briefing call to discuss the Company’s financial results through September 30, 2016 and its business outlook. Directly following the quarterly briefing, the Company will provide an extended discussion of the clinical data results released at the Transcatheter Cardiovascular Therapeutics (“TCT”) conference held this week in Washington, D.C. Ms. Reggie Groves, the Company’s Chief Executive Officer, will host the call.
The call is scheduled for 2:00 p.m. US PST on Wednesday, November 9, 2016 (which is 9:00 a.m. AEDT on Thursday, 10 November 2016) and may be accessed toll-free within the United States and Canada by dialing 1-877-312-5413 five minutes prior to the scheduled start time. Callers in Australia may access the call by dialing 1800 005 989. If you are asked to provide an access code, please spell out the word “REVA” to the operator and you will be connected promptly.
If you reside outside of the United States, Canada, or Australia, or if you prefer to access the audiocast through our website, please visit “Events & Presentations” under the “Investors” section of our website at www.revamedical.com, and click on the “listen to webcast” link. A replay of the audiocast will be available on our website after the call.
About REVA
REVA is a clinical stage medical device company located in San Diego, California, USA, that is working to commercialize its proprietary bioresorbable scaffolds, as an alternative to metal stents, to treat coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, then disappear (or “resorb”) from the body over a period of time. This resorption allows the return of natural movement and function of the artery, a result not attainable with permanent metal stents. The Company’s Fantom® scaffold has been designed to offer an ideal balance of thinness and strength, with distinct ease-of-use features including complete scaffold visibility under x-ray, expansion with one continuous inflation, and no procedural time limitations. REVA will require regulatory approval before it can commercialize Fantom or any other product.